Compare MAMA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAMA | CTNM |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 550.7M |
| IPO Year | 2011 | 2024 |
| Metric | MAMA | CTNM |
|---|---|---|
| Price | $17.74 | $14.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $19.00 | $19.00 |
| AVG Volume (30 Days) | ★ 467.2K | 239.7K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | 0.46 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $31.09 | N/A |
| Revenue Next Year | $16.12 | N/A |
| P/E Ratio | $352.20 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $7.90 | $6.56 |
| 52 Week High | $21.00 | $16.91 |
| Indicator | MAMA | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 54.23 |
| Support Level | $17.37 | $13.50 |
| Resistance Level | $19.52 | $15.52 |
| Average True Range (ATR) | 0.74 | 1.13 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 48.42 | 56.40 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.